@article{97258,
  keywords = {General Medicine, Surgery},
  author = {Uwishema O and Sapkota S and Wellington J and Onyeaka CVP and Onyeaka H},
  title = {Leishmaniasis control in the light of the COVID-19 pandemic in Africa},
  abstract = {<p>Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease 2019 (COVID-19) pandemic that impacted resource distribution and access to medication. Continuous effort in vaccine development and affordable therapeutics are necessary to eliminate leishmaniasis in low-income countries. Further research is necessary to determine molecular drug resistance markers in leishmaniasis patients. In this analysis, we focus on the effect of COVID-19 on leishmaniasis in Africa.</p>
},
  year = {2022},
  journal = {Annals of Medicine and Surgery},
  pages = {104263},
  publisher = {Elsevier BV},
  issn = {2049-0801},
  url = {https://www.sciencedirect.com/science/article/pii/S2049080122010238/pdfft?md5=5e1709834eb660d3fccbd2603514a82b&pid=1-s2.0-S2049080122010238-main.pdf},
  doi = {10.1016/j.amsu.2022.104263},
  language = {eng},
}